Citi concerned by possible Genmab data delay
US-based Citi has identified a risk that the schedule for Genmab’s comparative study between GEN3014 and Darzalex Faspro may not hold up, and data might not be published until 2025.
by MARKETWIRE
US-based bank Citi likes Genmab, but not the company’s share price. This is the message in a new note in which the bank raises its price target but reiterates its ”sell” recommendation.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA grants Genmab cancer drug priority review status
For subscribers
Zealand Pharma open to being acquired
For subscribers
